< Topic >For example intraperitoneal, adhesion formation after the chest and the vertebral operation becomes the contraction after the principal technique and cause of the death. It is researched, toranirasuto as the adhesion inhibiter, but value and propriety of the research regarding the effect of systemic dosage of toranirasuto to control or prevention of adhesion are doubtful.SolutionsThis invention, control law of adhesion formation after the internal technique between the organizational surface of the coelom which is offered to operation being, although you control the adhesion formation with the particular surface, the effective quantity and, the direct under conditions, regards control law, and are suited for the use with local non systemic dosage of the medicine to the body, and local non systemic dosage of the direct medicine to organization inside the coelom which is offered to operation the delivery vehicle and the composition which include toranirasuto to the organizational surface of the coelom or the dosage of that analog.< Selective figure >It is not【課題】例えば腹腔、胸部および脊椎手術後の癒着形成は、主要な術後罹病および死亡原因となる。トラニラストが癒着防止剤として研究されているが、癒着の抑制または防止へのトラニラストの全身投与の効果に関する研究の価値および妥当性は疑わしい。【解決手段】本発明は、手術に供した体腔の組織表面間の体内術後癒着形成の抑制法であって、当該表面での癒着形成を抑制するのに有効な量および条件での、直接的な、体腔の組織表面へのトラニラストまたはその類似体の投与を含む抑制法、ならびに、身体への薬剤の局所非全身投与、および手術に供した体腔内の組織への直接的な薬剤の局所非全身投与での使用に適した送達ビヒクルおよび組成物に関する。【選択図】なし
